An Insider Kevin Cornwell Sold 3967 shares of Utah Medical Products, Inc. (UTMD); 9 Analysts Are Bullish Teva Pharmaceutical Industries Limited (TEVA) Last Week

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Logo

Among 35 analysts covering Teva Pharma (NYSE:TEVA), 9 have Buy rating, 8 Sell and 18 Hold. Therefore 26% are positive. Teva Pharma had 157 analyst reports since July 21, 2015 according to SRatingsIntel. The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) has “Perform” rating given on Thursday, August 3 by Oppenheimer. The firm earned “Overweight” rating on Monday, August 3 by JP Morgan. The rating was maintained by Jefferies on Tuesday, July 25 with “Hold”. The stock has “Hold” rating by Maxim Group on Thursday, July 13. Leerink Swann maintained Teva Pharmaceutical Industries Limited (NYSE:TEVA) rating on Tuesday, July 21. Leerink Swann has “Outperform” rating and $74 target. Mizuho maintained Teva Pharmaceutical Industries Limited (NYSE:TEVA) rating on Monday, May 7. Mizuho has “Buy” rating and $2700 target. The firm has “Hold” rating by Gabelli given on Friday, February 9. The rating was downgraded by Credit Suisse to “Neutral” on Friday, August 4. As per Thursday, February 8, the company rating was maintained by Cowen & Co. The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) earned “Neutral” rating by BTIG Research on Wednesday, November 16. See Teva Pharmaceutical Industries Limited (NYSE:TEVA) latest ratings:

11/06/2018 Broker: Leerink Swann Rating: Sell New Target: $16.0000 Maintain
31/05/2018 Broker: Citigroup Old Rating: Buy New Rating: Buy Old Target: $24 New Target: $25 Maintain
24/05/2018 Broker: Guggenheim Rating: Hold Maintain
24/05/2018 Broker: Barclays Capital Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $13 New Target: $20 Maintain
07/05/2018 Broker: Mizuho Rating: Buy New Target: $27.0000 Maintain
07/05/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $18 Maintain
03/05/2018 Broker: Wells Fargo Rating: Sell New Target: $16.5000 Maintain
20/04/2018 Broker: Mizuho Rating: Buy New Target: $27.0000 Maintain
25/03/2018 Broker: RBC Capital Markets Rating: Hold New Target: $16.0000 Maintain
20/03/2018 Broker: Jefferies Rating: Hold New Target: $19.0 Maintain

Another recent and important Utah Medical Products, Inc. (NASDAQ:UTMD) news was published by Nasdaq.com which published an article titled: “New Research Coverage Highlights Franklin Electric Co., ForeScout Technologies, State Bank Financial, Meta ..” on May 25, 2018.

A few days ago, the Chairman – CEO – Secretary of Utah Medical Products Inc, Mr. Kevin Cornwell, made a sale of number of shares – 3,967, totalling $417,429 USD, which is based on a stock price of $105.2 of a share. This is not his first insider trade, in the last 30 days, he unloaded another 7,953 shares worth $835,349 USD. The sale was dated 13/06/2018 and was disclosed in a document filed with the U.S. Security & Exchange Commission. The document is accessible online here. At the moment, he has a total of 442,411 shares or 11.86% of Utah Medical Products Inc’s total market cap.

Since February 2, 2018, it had 0 buys, and 15 sales for $3.69 million activity. Shares for $134,673 were sold by HOYER ERNST G on Thursday, February 8. $251,569 worth of Utah Medical Products, Inc. (NASDAQ:UTMD) was sold by PAYNE BARBARA A. $599,970 worth of Utah Medical Products, Inc. (NASDAQ:UTMD) was sold by CORNWELL KEVIN L on Tuesday, June 5.

Utah Medical Products, Inc. develops, makes, and distributes medical devices for the healthcare industry worldwide. The company has market cap of $387.60 million. It provides fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD, an infant respiratory hood; and DELTRAN PLUS, a blood pressure monitoring system. It has a 45.65 P/E ratio. The firm also offers umbilical vessel catheters; DIALY-NATE, a disposable peritoneal dialysis set; PALA-NATE, a silicone oral protection device; URI-CATH, a urinary drainage system; and MYELO-NATE, a lumbar sampling kit.

The stock decreased 0.43% or $0.45 during the last trading session, reaching $103.9. About 17,602 shares traded or 22.39% up from the average. Utah Medical Products, Inc. (NASDAQ:UTMD) has risen 57.69% since June 13, 2017 and is uptrending. It has outperformed by 45.12% the S&P500. Some Historical UTMD News: ; 19/04/2018 – DJ Utah Medical Products Inc, Inst Holders, 1Q 2018 (UTMD); 03/04/2018 Investor Expectations to Drive Momentum within Atrion, Curis, Independence Contract Drilling, Utah Medical Products, FutureFuel; 26/04/2018 – Utah Medical Products 1Q EPS $1.09; 08/05/2018 – Utah Medical Products, Inc. Announces Quarterly Dividend; 26/04/2018 – Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2018; 14/05/2018 – Lazard Asset Buys New 3% Position in Utah Medical; 08/05/2018 – Utah Medical Products Declares Dividend of 27c

Investors sentiment decreased to 1.21 in 2018 Q1. Its down 0.54, from 1.75 in 2017Q4. It fall, as 8 investors sold Utah Medical Products, Inc. shares while 25 reduced holdings. 18 funds opened positions while 22 raised stakes. 2.48 million shares or 3.44% more from 2.40 million shares in 2017Q4 were reported. Everett Harris And Ca holds 3,545 shares or 0.01% of its portfolio. Dimensional Fund Advsrs Limited Partnership stated it has 168,267 shares or 0.01% of all its holdings. 12,337 are owned by Deutsche Commercial Bank Ag. Geode Capital Mgmt Lc holds 0% in Utah Medical Products, Inc. (NASDAQ:UTMD) or 42,765 shares. Barclays Public Limited Liability owns 2,208 shares. Prudential Finance has invested 0% in Utah Medical Products, Inc. (NASDAQ:UTMD). Metropolitan Life Insurance Ny reported 0% of its portfolio in Utah Medical Products, Inc. (NASDAQ:UTMD). 25,481 were reported by Morgan Stanley. Sei Invests Commerce has 0% invested in Utah Medical Products, Inc. (NASDAQ:UTMD) for 4 shares. California Employees Retirement Sys accumulated 19,965 shares or 0% of the stock. 3,129 were accumulated by Rhumbline Advisers. Vanguard Gru Incorporated reported 127,199 shares. Blackrock Incorporated reported 161,883 shares. Great West Life Assurance Company Can has invested 0% of its portfolio in Utah Medical Products, Inc. (NASDAQ:UTMD). Alliancebernstein Limited Partnership, New York-based fund reported 2,600 shares.

Teva Pharmaceutical Industries Limited develops, makes, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. The company has market cap of $24.77 billion. It operates through two divisions, Generic Medicines and Specialty Medicines. It currently has negative earnings. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

More notable recent Teva Pharmaceutical Industries Limited (NYSE:TEVA) news were published by: Globes.Co.Il which released: “Teva well on the road to recovery” on June 13, 2018, also Globes.Co.Il with their article: “Tue: Teva rally fails to lift TASE” published on June 12, 2018, Seekingalpha.com published: “Buy Alibaba – Cramer’s Lightning Round (6/12/18)” on June 13, 2018. More interesting news about Teva Pharmaceutical Industries Limited (NYSE:TEVA) were released by: Globenewswire.com and their article: “Analysis: Positioning to Benefit within Teva Pharmaceutical Industries, Resonant, United Community Financial …” published on June 07, 2018 as well as Globes.Co.Il‘s news article titled: “Sun: Resurgent Teva fails to lift flat TASE” with publication date: June 10, 2018.

Utah Medical Products, Inc. (NASDAQ:UTMD) Institutional Positions Chart